The Story of Risperidone: From an LSD Model to the Atypical Revolution
The Setting: Beerse, Belgium, Early 1980s
Nearly three decades after Paul Janssen had synthesized haloperidol, his research group at Janssen Pharmaceutica remained one of the few places in the world where psychiatric drug discovery was treated as pure experimental science.
By the early 1980s, the limits of typical antipsychotics were painfully clear: haloperidol and chlorpromazine controlled hallucinations and delusions, but at the cost of crippling extrapyramidal symptoms, tardive dyskinesia, and emotional flatness. Patients often traded psychosis for a chemical straitjacket.
The Janssen team, led by pharmacologist François Colpaert and guided by Paul Janssen’s insistence on unconventional thinking, decided to approach schizophrenia from a completely different angle.
The Unusual Hypothesis: The LSD Model
Most pharmaceutical laboratories of that era screened compounds for their ability to block amphetamine psychosis or induce catalepsy in rats.
The Janssen group instead turned to lysergic acid diethylamide (LSD).
Their reasoning was elegant: if LSD produced a state in healthy humans that phenomenologically resembled the perceptual distortions of schizophrenia, then perhaps blocking the interoceptive effects of LSD in animals could identify an antipsychotic that worked on the perceptual and cognitive dimensions of psychosis, not just the motoric ones.
This became known as the “LSD model of psychopathology.”
It was considered heretical at the time because the rest of the field was chasing dopamine blockade. Janssen’s team was instead asking: Can we find a molecule that antagonizes the perceptual effects of LSD without simply sedating the animal?
The Synthesis of R64766 (Risperidone)
In 1984, Janssen chemists synthesized a new benzisoxazole derivative, codenamed R64766. The compound was structurally distinct from the butyrophenones (like haloperidol) and the phenothiazines. It was a combined antagonist: highly potent at serotonin 5-HT₂A receptors and at dopamine D₂ receptors, but with a markedly higher affinity for the serotonin receptor.
In animal models, R64766 blocked the discriminative stimulus effects of LSD — meaning rats trained to recognize an LSD cue could no longer detect it after receiving R64766. Critically, this blockade occurred without producing the heavy catalepsy and sedation typical of haloperidol.
Pharmacological Meaning
This serotonergic-dopaminergic profile was the birth of what would later be called the “atypical” antipsychotic. The high 5-HT₂A/D₂ ratio was the secret: by blocking serotonin receptors in the prefrontal cortex while gently modulating dopamine in the mesolimbic pathway, the drug seemed to separate antipsychotic efficacy from motor side effects.
Janssen’s team also introduced the concept of “response quality” in receptor theory — the idea that not all receptor antagonisms are pharmacologically equal. It was not enough to simply block dopamine; the quality of the behavioral output mattered.
Clinical Trials and Launch
Risperidone entered clinical trials in the late 1980s. Trials in Belgium and across Europe demonstrated that it reduced positive symptoms of schizophrenia with a significantly lower burden of extrapyramidal side effects than haloperidol. It did not cause the same degree of akathisia or dystonia, though it was not free of side effects — weight gain, hyperprolactinemia, and later concerns about metabolic syndrome would emerge.
- First launched in Europe: 1993
- FDA approval in the United States: 1993
- Brand name: Risperdal®
The Reciprocal Impact on Psychiatry
Risperidone did not merely treat schizophrenia; it reshaped the scientific understanding of the disorder. It forced the field to move beyond the simple dopamine hypothesis and accept that serotonin, glutamate, and the interactions between multiple neurotransmitter systems were critical to psychosis.
By the late 1990s, risperidone had become the benchmark against which every new antipsychotic was measured. It enabled the deinstitutionalization movement to continue where haloperidol had stalled — because patients could now remain stable without the telltale Parkinsonian shuffle and facial rigidity that had stigmatized the earlier generation.
It also opened commercial and scientific floodgates: olanzapine, quetiapine, ziprasidone, and aripiprazole all followed, each trying to optimize the 5-HT₂A/D₂ balance that Janssen’s team had first identified in that small Belgian laboratory.
In one sentence: Risperidone was discovered in 1984 at Janssen Pharmaceutica by a team that used an LSD-antagonism model to screen for drugs that could treat psychosis without producing the motor rigidity of older antipsychotics — becoming the first blockbuster atypical antipsychotic and the template for modern schizophrenia pharmacology.

